Abstract: Immune checkpoint inhibitors(ICIs) has revolutionized the treatment of cancer. However, with the rapid application of CPIs, the immune-related adverse events (irAE) have attracted more and more attention. irAE can occur in almost all organs, but rheumatic irAE seems to have different clinical characteristics. This article reviews the epidemiology, clinical characteristics and management principles of rheumatic irAE caused by ICIs treatment, and discusses its potential pathogenesis.